Clinical trial · no report yet · Phase 3
ACT-1
Alemtuzumab and CHOP in T-cell Lymphoma
- NCT00646854 ↗
- Completed
- Aarhus University Hospital
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Lymphoma, T-Cell, Peripheral
- Interventions
- CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab; CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
- Arms
- Arm A · Active comparator
- Arm B · Experimental
- Enrollment
- 136
- Primary outcomes
- Event-free Survival
- Sponsor
- Aarhus University Hospital with GCP-unit at Aarhus University Hospital, Aarhus, Denmark
- Start
- Jun 2008
- Primary completion
- Dec 31, 2016
- Results posted
- No
- Registry record
- NCT00646854 · updated Mar 1, 2019